Leveraging Innovation to Mitigate Risk During Heart Surgery
Authors:
Open Access
- 1 May 2023
- journal article
- conference paper
- Published by Texas Heart Institute Journal in Texas Heart Institute Journal
- Vol. 50 (3)
Abstract
Innovation is not necessarily about the “next big thing” according to Mehta.1 Instead, innovation can occur by combining existing technologies, developing small ideas that compound, or evolving to address problems that have arisen from previous innovations that yielded unpredictable consequences. Innovation in the field of cardiovascular surgery is no different. As the field becomes progressively less invasive through innovation, patients who require open cardiac surgery are increasingly complex and carry increased risk. Patients with ischemic cardiomyopathy at high risk for morbidity often require surgical revascularization and valve interventions; however, risk factors such as diminished ejection fraction, redo operation, and multiple comorbidities compound perioperative morbidity and operative mortality. This report will define high-risk cardiac surgery and discuss how surgeons can leverage innovation to mitigate risk.The Surgical Treatment for Ischemic Heart Failure (STICH) trial randomized 1,212 patients with left ventricular ejection fraction (LVEF) of 35% or less and coronary artery disease suitable for surgical revascularization to coronary artery bypass grafting (CABG) or guideline-directed medical therapy (GDMT).2 There was some crossover, but the initial analysis was done based on intention to treat. Among the 610 patients who were randomly assigned to the CABG group, 555 (91.0%) underwent CABG before completion of the trial. Among the 602 patients who were randomly assigned to the medical therapy group, 119 (19.8%) underwent CABG at any time before the completion of long-term follow-up. At median follow-up of 9.8 years, the CABG group had significantly lower risk of death from any cause with a hazard ratio (HR) of 0.84 (95% CI, 0.73–0.97, P = .02) as well as lower risk of death from cardiovascular cause (P = .006), hospitalization for heart failure (P = .002), nonfatal myocardial infarction (MI) (P = .03), or nonfatal stroke (P = .03) (Fig. 1).2 The results remained consistent following analysis of crossovers. Of all patients who ultimately underwent CABG, 57% died during follow-up compared with 68% of those who underwent GDMT alone (HR, 0.75; 95% CI, 0.65–0.87; P < .001). The number needed to treat was 14 to save 1 life over 10 years with CABG.Sun and coauthors3 reviewed 12,113 patients with LVEF less than 35% and coronary disease appropriate for surgical revascularization who underwent percutaneous coronary intervention or CABG in Ontario, Canada. Propensity matching yielded 2,397 patients in each group. Patients who underwent percutaneous coronary intervention had significantly higher mortality rates (HR, 1.6; 95% CI, 1.3–1.7), cardiac morbidity (HR, 2.0; 95% CI, 1.9–2.2), repeat revascularization (HR, 3.7; 95% CI, 3.2–4.3), and hospitalization for MI (HR, 3.2; 95% CI, 2.6–3.8) or heart failure (HR, 1.5; 95% CI, 1.3–1.6) than did those who underwent CABG. These 2 studies support an aggressive surgical approach in patients with ischemic cardiomyopathy to improve long-term outcomes. Patients with ischemic cardiomyopathy live longer and have less cardiac morbidity with surgical revascularization. Stable patients with ischemic cardiomyopathy, however, have a higher 30-day mortality rate with CABG than with GDMT alone because of the acute surgical risk (4% vs 1% in STICH).2 Thus, there is a need to explore options to decrease upfront morbidity and mortality in patients who require high-risk cardiac surgical intervention.Use of the Society for Thoracic Surgery risk calculator is often not accurate at the high end of risk for morbidity, especially in patients undergoing reoperative surgery.4 Because of the magnitude of the data sets used to develop modern risk calculators, lesser common but very effective risk factors may be overshadowed by other more common risk factors and not reach statistical significance in multivariate analysis. For example, cirrhosis and liver failure have a profound effect on outcomes of any procedure, but neither is included in most cardiac surgery risk algorithms. In addition, frailty is a more recent addition to the preoperative evaluation of patients to determine fitness for transcatheter procedures; however, it does not affect risk prediction calculators for open procedures. High-risk cardiac surgery must be determined through assessment of a combination of objective and subjective criteria.A survey of cardiac surgeons identified low LVEF as the most important risk factor, followed by elevated EuroSCORE, and redo surgery.5 Elevated creatinine levels, tight left main stenosis with unstable angina, and elevated troponin and brain natriuretic peptide levels were also considered, but to a lesser degree. The Toronto General Hospital group reported a 9% incidence of low cardiac output syndrome (LCOS) among 4,558 patients undergoing CABG.6 Low cardiac output syndrome was defined as the need for intra-aortic balloon pump (IABP) or inotropes for more than 30 minutes postoperatively to maintain a systolic blood pressure greater than 90 mm Hg and a cardiac index greater than 2.2 L/min/m2. The mortality rate was much higher at 17% in those with LCOS than in patients with LCOS (17% vs 0.9%; P < .001). The most important risk factors for LCOS were: (1) LVEF less than 20% (27% incidence of LCOS in these patients; HR, 5.7), (2) reoperative surgery (25%; HR, 4.4), and (3) emergency operation (27%; HR, 3.7). Other significant factors included female sex (16%; HR, 2.5), diabetes (13%; HR, 1.6), age older than 70 years (13%; HR, 1.5), left main coronary artery disease (12%; HR, 1.4), recent MI (16%; HR, 1.4), and triple-vessel disease (10%; HR, 1.3). Strategies for optimization should focus on patients with poor left ventricular (LV) function and those undergoing reoperative surgery.Preoperative assessment of organ dysfunction should be performed. Correction of preoperative anemia may result in fewer blood...Keywords
This publication has 20 references indexed in Scilit:
- Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac SurgeryNew England Journal of Medicine, 2017
- Preoperative Prophylactic Intraaortic Balloon Pump Reduces the Incidence of Postoperative Acute Kidney Injury and Short-Term Death of High-Risk Patients Undergoing Coronary Artery Bypass Grafting: A Meta-Analysis of 17 StudiesThe Annals of Thoracic Surgery, 2016
- Coronary-Artery Bypass Surgery in Patients with Ischemic CardiomyopathyNew England Journal of Medicine, 2016
- The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trialsBritish Journal of Anaesthesia, 2015
- A Bayesian network meta-analysis on the effect of inodilatory agents on mortalityBritish Journal of Anaesthesia, 2015
- Pre-operative intra aortic balloon pumps in patients undergoing coronary artery bypass graftingCochrane Database of Systematic Reviews, 2011
- High-Risk Mitral Valve Surgery: Perioperative Hemodynamic Optimization with Nesiritide (BNP)The Annals of Thoracic Surgery, 2005
- Optimal timing of preoperative intraaortic balloon pump support in high-risk coronary patientsThe Annals of Thoracic Surgery, 1999
- Preoperative Intraaortic Balloon Pump Enhances Cardiac Performance and Improves the Outcome of Redo CABGThe Annals of Thoracic Surgery, 1997
- Predictors of low cardiac output syndrome after coronary artery bypassThe Journal of Thoracic and Cardiovascular Surgery, 1996